BMRN Stock Analysis: Biomarin Pharmaceutical | NASDAQ
Biotechnology | NASDAQ, USA | Market Cap: 10.774m USD | 12M Return: 8.6% | US09061G1013 | Charts, Fundamentals & Technical Analysis
Avg Turnover: 145M
EPS Trend: 31.7%
Qual. Beats: 1
Rev. Trend: 53.5%
Qual. Beats: 2
Warnings
Tailwinds
Seasonality 11.7 years of data
How good or bad each month usually is (without trend). The score below shows how much you can trust it: 0 = pure chance, >40 gets interesting and >55 is strong.
BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) is a U.S.-based biotechnology company headquartered in San Rafael, California, founded in 1996. It develops and commercializes therapies for life-threatening rare diseases, operating across the United States, Europe, Latin America, the Middle East, and Asia Pacific. The company serves specialty pharmacies, hospitals, non-U.S. government agencies, distributors, and pharmaceutical wholesalers, and maintains a license and collaboration agreement with Ares Trading S.A.
Its commercial portfolio includes Vimizim (MPS IV type A), Voxzogo (achondroplasia), Naglazyme (MPS VI), Palynziq (phenylketonuria), Brineura (Batten disease), Aldurazyme, and Kuvan. The pipeline features BMN 333, a longer-acting CNP for growth disorders, and BMN 351, an oligonucleotide for Duchenne muscular dystrophy.
BioMarin operates within the orphan drug business model, targeting rare genetic conditions with limited patient populations. This approach typically relies on enzyme replacement therapies and biologics, which often qualify for orphan drug designation and extended market exclusivity periods, supporting premium pricing strategies common in the rare disease segment.
- VOXZOGO sales accelerate in achondroplasia market
- PALYNZIQ revenue grows in PKU segment
- Pipeline assets BMN 333 and BMN 351 advance
| Net Income: -123b TTM > 0 and > 6% of Revenue |
| FCF/TA: 0.04 > 0.02 and ΔFCF/TA -6.53 > 1.0 |
| NWC/Revenue: 225.4% < 20% (prev 98.78%; Δ 126.7% < -1%) |
| CFO/TA 0.05 > 3% & CFO 577b > Net Income -123b |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 2.44 > 1.5 & < 3 |
| Outstanding Shares: last quarter (193.6m) vs 12m ago 0.81% < -2% |
| Gross Margin: 79.94% > 18% (prev 81.32%; Δ -1.39% > 0.5%) |
| Asset Turnover: 17.75% > 50% (prev 40.63%; Δ -22.88% > 0%) |
| Interest Coverage Ratio: -1.47 > 6 (EBIT TTM -81.8b / Interest Expense TTM 55.7b) |
| A: 0.20 (Total Current Assets 3921b - Total Current Liabilities 1605b) / Total Assets 11569b |
| B: 0.02 (Retained Earnings 182b / Total Assets 11569b) |
| C: -0.01 (EBIT TTM -81.8b / Avg Total Assets 5788b) |
| D: 1.18 (Book Value of Equity 6256b / Total Liabilities 5313b) |
| Altman-Z'' = 2.51 = A |
| DSRI: 3.0 (Receivables 1076b/790.3m, Revenue 1027b/3.09b) |
| GMI: 1.02 (GM 81.32% / 79.94%) |
| AQI: 1.61 (AQ_t 0.58 / AQ_t-1 0.36) |
| SGI: 332.0 (Revenue 1027b / 3.09b) |
| TATA: -0.06 (NI -123b - CFO 577b) / TA 11569b) |
| Beneish M = 236.3 (Cap -4..+1) = D |
As of November 10, 2026, the stock is trading at USD 57.18 with a total of 2,066,729 shares traded. Over the past week, the price has changed by -0.45%, over one month by +4.34%, over three months by -16.99% and over the past year by +8.56%.
Current recommended Stop Loss: 52.40 (which is 8.4% or 2.6 ATR below the current price).
Biomarin Pharmaceutical has received a consensus analysts rating of 4.32. Therefore, it is recommended to buy BMRN.
- StrongBuy: 16
- Buy: 5
- Hold: 7
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 91.3 | 59.7% |
P/E Forward = 8.881
P/S = 3.1628
P/B = 1.7916
P/EG = 0.3444
Revenue TTM = 1027b USD
EBIT TTM = -81.8b USD
EBITDA TTM = -81.7b USD
Long Term Debt = 597.2m USD (from longTermDebt, last fiscal year)
Short Term Debt = 659b USD (from shortTermDebt, last quarter)
Debt = 659b USD (from shortLongTermDebtTotal, last quarter) + Leases 16.1m
Net Debt = -77.3b USD (calculated: Debt 659b - CCE 736b)
Enterprise Value = 10.8b USD (floored to Market Cap, CCE > MCap+Debt)
Interest Coverage Ratio = -1.47 (Ebit TTM -81.8b / Interest Expense TTM 55.7b)
EV/FCF = 0.02x (Enterprise Value 10.8b / FCF TTM 499b)
FCF Yield = 4.63k% (FCF TTM 499b / Enterprise Value 10.8b)
FCF Margin = 48.58% (FCF TTM 499b / Revenue TTM 1027b)
Net Margin = -11.95% (Net Income TTM -123b / Revenue TTM 1027b)
Gross Margin = 79.94% ((Revenue TTM 1027b - Cost of Revenue TTM 206b) / Revenue TTM)
Gross Margin QoQ = 79.95% (prev 79.51%)
Tobins Q-Ratio = 0.00 (Enterprise Value 10.8b / Total Assets 11569b)
Interest Expense / Debt = 8.46% (Interest Expense 55.7b / Debt 659b)
Taxrate = 27.69% (133.6m / 482.5m)
NOPAT = -59.1b (EBIT -81.8b * (1 - 27.69%)) [loss with tax shield]
Current Ratio = 2.44 (Total Current Assets 3921b / Total Current Liabilities 1605b)
Debt / Equity = 0.11 (Debt 659b / totalStockholderEquity, last quarter 6256b)
Debt / EBITDA = 0.95 (negative EBITDA) (Net Debt -77.3b / EBITDA -81.7b)
Debt / FCF = -0.15 (Net Debt -77.3b / FCF TTM 499b)
Total Stockholder Equity = 1569b (last 4 quarters mean from totalStockholderEquity)
RoA = -2.12% (Net Income -123b / Total Assets 11569b)
RoE = -7.82% (Net Income TTM -123b / Total Stockholder Equity 1569b)
RoCE = -5.21% (EBIT -81.8b / Capital Employed (Equity 1569b + L.T.Debt 597.2m))
RoIC = -0.56% (negative operating profit) (NOPAT -59.1b / Invested Capital 10572b)
WACC = 6.13% (E(10.8b)/V(670b) * Re(6.71%) + D(659b)/V(670b) * Rd(8.46%) * (1-Tc(0.28)))
Discount Rate = 6.71% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: -60.89 | Cagr: -1.55%
[DCF] Terminal Value 77.97% ; FCFF base≈300b ; Y1≈344b ; Y5≈506b
[DCF] Fair Price = 39.7k (EV 7610b - Net Debt -77.3b = Equity 7687b / Shares 193.6m; r=8.35% [WACC [floored]]; 5y FCF grow 15.0% → 2.50% )
EPS Correlation: 31.66 | EPS CAGR: 9.91% | SUE: 1.28 | # QB: 1
Revenue Correlation: 53.52 | Revenue CAGR: 174.1% | SUE: 4.0 | # QB: 2
EPS current Year (2026-12-31): EPS=3.16 | Chg30d=-27.44% | Revisions=-73% | GrowthEPS=+0.3% | GrowthRev=+20.5%
EPS next Year (2027-12-31): EPS=6.39 | Chg30d=-10.93% | Revisions=-30% | GrowthEPS=+102.1% | GrowthRev=+15.0%
[Analyst] Revisions Ratio: -61% (up=2, down=13)